Here in Vermont. Editorial.

J Relig Health

Published: December 2009

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10943-009-9299-xDOI Listing

Publication Analysis

Top Keywords

vermont editorial
4
vermont
1

Similar Publications

Dexmedetomidine for analgesia and sedation for procedural pain or discomfort in newborn infants.

Cochrane Database Syst Rev

January 2025

Department of Clinical Sciences Lund, Paediatrics, Lund University, Skåne University Hospital, Lund, Sweden.

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of dexmedetomidine compared with opioids, non-opioids and placebo in providing sedation and analgesia for procedural pain in newborn infants.

View Article and Find Full Text PDF

Individualized developmental care interventions for promoting development and preventing morbidity in preterm infants.

Cochrane Database Syst Rev

January 2025

Cochrane Sweden, Department of Research, Development, Education and Innovation, Lund University, Skåne University Hospital, Lund, Sweden.

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of individualized developmental care interventions for promoting development and preventing morbidity in preterm infants.

View Article and Find Full Text PDF

This editorial focuses on the issue of data misuse that is increasingly evidenced in social media as well as some premiere scientific journals. This issue is of critical importance to open science projects in general, and ABCD in particular, given the broad array of biological, behavioural and environmental information collected on this American sample of 12,000 youth and parents. ABCD data are already widely used with over 1,200 publications and twice as many citations per year as expected (relative citation index based on year, field and journal).

View Article and Find Full Text PDF

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Cytotherapy

January 2025

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.

View Article and Find Full Text PDF

Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective modulator therapy (HEMT) in young children with cystic fibrosis (YCwCF) on these disease complications is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!